Stayble Therapeutics AB (SE:STABL)
:STABL
Want to see SE:STABL full AI Analyst Report?
STABL Stock Chart & Stats
kr0.24
kr0.07(17.59%)
At close: 4:00 PM EST
kr0.24
kr0.07(17.59%)
Day’s Range― - ―
52-Week Rangekr0.03 - kr0.65
Previous CloseN/A
Volume514.07K
Average Volume (3M)378.51K
Market Cap
kr13.90M
Enterprise Valuekr12.80M
Total Cash (Recent Filing)kr2.45M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume398,578
30 Day Avg. Volume378,512
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnOperating cash burn has narrowed materially over several years, indicating the company is trending toward lower funding needs. This durable improvement lengthens runway and raises the chance management can reach near-term clinical milestones without immediate dilutive financing.
Low LeverageNear-zero reported debt provides financial flexibility and reduces default risk, allowing the firm to prioritize R&D funding or opportunistic financing on better terms. Low leverage is a lasting structural advantage for a clinical-stage biotech.
Focused Clinical-stage PipelineA clear, focused lead asset (STA363) targeting chronic low back pain concentrates management resources and de-risks portfolio distraction. For a small biotech, a single prioritized program can accelerate decision making and clinical progress over the coming months.
Bears Say
Pre-revenue ProfileAbsence of product revenue means the business lacks commercial validation and is wholly reliant on clinical success and external funding. This structural status increases execution risk and prolongs the timeline to sustainable cash generation.
Persistent Negative Cash FlowSustained negative operating and free cash flow depletes reserves and forces recurring capital raises. Over 2–6 months this constraint can limit ability to fund trials or require dilutive financing, materially affecting strategic flexibility and long-term plan execution.
Shrinking Equity BaseRapidly contracting shareholders' equity reflects accumulated losses and reduces the balance-sheet buffer against shocks. A compressed equity base limits borrowing capacity and magnifies the impact of additional losses or funding needs, raising solvency and dilution risks.
STABL FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was kr0.03 and its highest was kr0.65 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is kr13.90M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Stayble Therapeutics AB’s earnings last quarter?
Currently, no data Available
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 64,359,795 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in SE:STABL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.